Drug Discovery & DDS– category –
-
ABL Bio’s Bispecific EGFR/MUC1 ADC, ABL209, Progresses in US Phase 1 Trial, Preclinical Data Presented at World ADC Korea
Seoul Economic Daily South Korea Overview ABL Bio unveiled preclinical data for its bispecific ADC candidate, ABL209 (NEOK002), currently in US Phase 1 clinical trials, at the 5th World ADC South Korea 2026. ABL209 targets both EGFR and ... -
AI/Machine Learning Drives Target Identification and Precision Nanomedicine in Drug Discovery, Enhancing Candidate Selection and Pathway Analysis
Dove Medical Press USA Overview Machine learning (ML) and deep learning (DL) strategies are advancing drug discovery by enhancing target identification and precision nanomedicine. These technologies leverage virtual screening and bioacti... -
Integrating AI and Nodal Biology Accelerates Cell Response Prediction, Building Future Drug Discovery Engine
amacad.org USA Overview The integration of artificial intelligence with "nodal biology" is poised to revolutionize drug discovery by accelerating target identification through predicting human cellular responses to disease perturbations.... -
AlphaFold and AlphaFold 3 Revolutionize Protein Structure and Interaction Prediction, Significantly Accelerating Drug Discovery
IntuitionLabs / dev.to USA Overview AlphaFold and its successor, AlphaFold 3, are dramatically advancing protein structure and molecular interaction prediction, significantly compressing traditional drug discovery timelines. AlphaFold 3 ... -
FDA Approves Oral Peptide Icorokinra for Moderate-to-Severe Plaque Psoriasis, Driven by Advanced DDS
Dermatology Times USA Overview The FDA has approved icorokinra, the first oral IL-23 receptor antagonist peptide for moderate-to-severe plaque psoriasis, representing a significant breakthrough in oral peptide delivery systems (DDS). Thi... -
Drug Discovery & DDS Weekly Report May 7, 2026
📄 Weekly Report June 07, 2026 (PDF) — Download Weekly Report June 07, 2026 (PDF) — DownloadDownload 🎙 Podcast June 07, 2026 (MP3) — Play & Download DrugDiscovery_DDSEnglishPodcast_20260607.mp3Download -
Aurobindo Pharma Inaugurates ₹10 Billion (USD 120M) TheraNym Biologics CDMO Plant in India, Expanding Capacity by 25,000L
Sahi India Overview Aurobindo Pharma announced the inauguration of its state-of-the-art ₹10 billion (approx. USD 120 million) TheraNym biologics CDMO facility in Hyderabad, India. This plant adds 25,000 liters of mammalian cell culture c... -
FDA Grants Breakthrough Therapy Designation to Merck’s Investigational KRAS G12C Inhibitor Calderasib (MK-1084) in Combination with KEYTRUDA for Metastatic NSCLC
BioSpace USA Overview Merck announced that its investigational oral KRAS G12C inhibitor, calderasib (MK-1084), in combination with KEYTRUDA® (pembrolizumab), received FDA Breakthrough Therapy Designation for newly diagnosed metastatic KR... -
Mount Sinai Scientists Discover Hidden Drug-Binding Pocket in Cancer Protein PKMYT1, Highlighting AI Drug Discovery’s Capabilities and Limitations
Mount Sinai - New York USA Overview Mount Sinai scientists discovered a previously overlooked drug-binding pocket in the cancer-related protein PKMYT1. This finding, while highlighting AI drug discovery's capabilities and limitations, op... -
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy (SMA)
PMLiVE USA Overview Biogen's investigational antisense oligonucleotide (ASO), salanersen, has received FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy (SMA). This designation is based on early clinical data showing impro...
